DPLO – diplomat pharmacy inc (US:NYSE)

DELAYED

^$ usd


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

1D

5D

1M

3M

YTD

1Y

3Y

1 Day DPLO SPY QQQ SPX

Date

Time

Symbol

Headline

Impact

Diplomat to Release Q1 2018 Operating Results, Host Conference Call on May 7

BRIEF-Diplomat Pharmacy Says Selling Shareholders To Sell Up To 4.1 Mln Shares Of Company [Reuters]

Diplomat to Present at 2018 Needham & Company Healthcare Conference

Diplomat to Present at 2018 Barclays Global Healthcare Conference

Diplomat Pharmacy Inc (NYSE: DPLO) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.

Diplomat Pharmacy Inc (NYSE: DPLO) was upgraded by analysts at Deutsche Bank AG from a "hold" rating to a "buy" rating.

Diplomat Pharmacy Thinks Its Strategy Is a "Huge Game Changer" [The Motley Fool]

Diplomat Pharmacy Inc (NYSE: DPLO) was given a new $28.00 price target on by analysts at Needham & Company LLC. They now have a "buy" rating on the stock.

Diplomat Pharmacy Inc (NYSE: DPLO) had its price target raised by analysts at Wells Fargo & Co from $21.50 to $25.00. They now have a "market perform" rating on the stock.

Diplomat Pharmacy Inc (NYSE: DPLO) had its price target lowered by analysts at Leerink Swann from $32.00 to $30.00. They now have an "outperform" rating on the stock.

Diplomat Pharmacy's (DPLO) CEO Jeff Park on Q4 2017 Results - Earnings Call Transcript [Seeking Alpha]

Diplomat Pharmacy's (DPLO) CEO Jeff Park on Q4 2017 Results - Earnings Call Transcript [Seeking Alpha]

BRIEF-Diplomat Pharmacy Posts Q4 Adj. Earnings Per Share $0.18 [Reuters]

Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance

Diplomat Pharmacy, Inc. to Host Earnings Call

Report: Developing Opportunities within Diplomat Pharmacy, Cogent Communications, Western Asset Mortgage Capital, Kimberly-Clark, Cincinnati Financial, and Cherry Hill Mortgage Investment - Future Expectations, Projections Moving into 2018

Diplomat Pharmacy Inc (NYSE: DPLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.

Diplomat Managing Rising Drug Costs to Support Patients

Diplomat to Release Fourth Quarter and 2017 Year End Financial Results, Provide 2018 Guidance and Host Conference Call On Monday, February 26, 2018

Diplomat Pharmacy Inc (NYSE: DPLO) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $35.00 price target on the stock.

Diplomat Pharmacy Inc (NYSE: DPLO) was downgraded by analysts at Deutsche Bank AG from a "buy" rating to a "hold" rating.

ThriveRx Wins ASPEN Clinical Nutrition Team of Distinction Award

Live Event:

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Earnings Week: Approaches for Trading the "Beat"

Facebook Reports Earnings Beat, Stock Surges

Alphabet Earnings Recap, Facebook Earnings Preview

Trading the Google Earnings Announcement: A Strategic Preview

Stock Market Week in Review + Bonus Friday Top Performer

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Earnings Week: Approaches for Trading the "Beat"

Facebook Reports Earnings Beat, Stock Surges

Alphabet Earnings Recap, Facebook Earnings Preview

Trading the Google Earnings Announcement: A Strategic Preview

Stock Market Week in Review + Bonus Friday Top Performer